OPTIBIOTIX HEALTH PLC - Full year results briefing
OptiBiotix Health plc (AIM:OPTI) delivered a strong investor update highlighting significant progress across revenue growth, global market expansion, and e-commerce performance. In FY2024, the company achieved a 35% increase in revenue and a 56% rise in sales orders - positioning it for a robust start to FY2025. E-commerce emerged as a major growth driver, with online sales up 108%, Amazon sales up 156%, and customer numbers expanding from 2,000 in 2022 to over 10,000. Strategic investments in the USA and India are delivering returns, including successful launches with partners such as Apollo and Morin in India, and new partnerships in North America. The company also cleared legacy inventory, lowered fixed costs, and is targeting improved EBITDA margins through streamlined operations and localized production. With leading positions in weight management and gut health, OptiBiotix is capitalizing on the demand for clinically backed functional nutrition, supported by 43 published studies. Its second-generation products and microbiome modulators present further upside potential. The business remains debt-free, holds over £9 million in cash, and owns stakes in high-growth associates like ProBiotix and SkinBioTherapeutics. With a diversified revenue mix across B2B, retail, and digital channels in key markets including Asia, Europe, and North America, OptiBiotix is well-positioned for scalable, sustainable growth. Investors are encouraged by the company’s strong order book, expanding customer base, and strategic focus on high-margin, recurring revenue streams.